Why Is AXOGEN INC (AXGN) Stock Up Today?

Axogen Inc (AXGN) shares surged 31.47% to close at $49.25, driven by strong third-quarter results and an upward revision to annual revenue guidance. The company reported a 26% jump in revenue and forecast total 2026 sales of at least $290 million, a figure that includes an additional $7 million from the recent BioCircuit acquisition.

What Happened

Axogen announced that its breast segment revenue grew by 60% during the period. Management indicated that the BioCircuit acquisition expands the company's reach in the nerve repair market, specifically through the addition of NerveTape growth potential. The company also outlined plans to develop its prostate market in 2027. Following the release, Mizuho raised its price target for the stock to $65, citing a positive growth outlook. Jefferies also increased its target to $60 from $55. The earnings call was led by Michael Dale, President, CEO, and Director, along with Lindsey Hartley.

What The Data Shows

The stock has gained 39.8% over the last eight sessions, moving from $35.24 to $49.25. On October 28, 2026, the stock printed 26 fresh 52-week highs and 2 fresh 52-week lows. The current price sits within the 52-week range of $17.14 to $52.91. Fundamentals show a market cap of $2.2 billion, with trailing twelve-month revenue up 23.6%. The company remains unprofitable with an EPS of -0.68 and a net margin of -13.4%. Its beta is 1.17. Unusual options activity included one notable print with $1.1 million in call premium and no put premium. Insider filings over the last 90 days show four sales totaling $4.7 million, with no buys. Recent sales were executed by directors Tyndall Joseph A. and Wendell Amy McBride, and EVP Marc A Began.

What To Watch

Axogen is scheduled to report its next quarterly earnings in the future, though no specific date was provided in the current data. Investors may monitor the breadth of analyst coverage, as 17 stories from 9 sources have appeared in the last 36 hours.